HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alexander J Engar Selected Research

BP-5-087

3/2015Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alexander J Engar Research Topics

Disease

1Leukemia
03/2015
1Neoplasms (Cancer)
03/2015
1Philadelphia Chromosome
03/2015
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2015

Drug/Important Bio-Agent (IBA)

1BP-5-087IBA
03/2015
1Tyrosine Kinase InhibitorsIBA
03/2015
1Phosphotransferases (Kinase)IBA
03/2015

Therapy/Procedure

1Therapeutics
03/2015